From: ambrygen.com Ambry Genetics® (Ambry), a leading clinical genetic testing company, announced today the launch of +RNAinsight™, a major advancement in genetic testing. +RNAinsight enables clinicians – for the first time ever – to conduct both DNA and RNA genetic testing at the same time. Substantially more often than DNA testing alone, this paired testing identifies whether someone has a genetic …
Putting patients front and centre
From: eyeforpharma.com When it comes to access, pharma can only gain by starting with the patient, says Takeda’s Liz Lewis ‘Access’ and ‘patient value’ are familiar terms in the pharma industry, but so often they are used in the abstract with little sense of what they mean to people at the receiving end of healthcare. Liz Lewis, Head of Global …
Let Life Happen Now Features “Paid Opportunities for the Cancer Community”
View PostIt’ll Take an Army to Kill the Emperor
By: Jacqueline Detwiler From: popularmechanics.com The men and women who are trying to bring down cancer are starting to join forces rather than work alone. Together, they are winning a few of the battles against the world’s fiercest disease. For this unprecedented special report, we visited elite cancer research centers around the country to find out where we are in …
HELIXAFE can detect the solid tumors during the genetic development phase, before they it are even formed
Source: Bioscience Institute From: prnewswire.com A study published in Cell Death & Disease demonstrates that cfDNA testing, marketed by Bioscience Institute SPA under the name HELIXAFE, can identify solid cancer development in healthy, asymptomatic people, in which cancer has not yet developed. Blood cell-free DNA (cfDNA) testing can be useful before cancer develops, in healthy people. This is the conclusion of the study published …
Cancer Centers Stretching To Keep Up With Pharma’s Oncology Interest
Source: BioPharma Dive From: pharmavoice.com A boom in cancer drug development has flooded the nation’s largest research institutions with clinical trial requests, which some say are making the system bloated and inefficient. “Most institutions have many more trials open than need to be open,” said John DiPersio, deputy director of the Alvin J. Siteman Cancer Center in St. Louis, home …
Top 5 Myths About Cancer Clinical Trials
By: Jill Weberding From: medium.com Clinical trials are the only avenue that advances in medicine occur. Every approved drug or treatment must go through the clinical trial process. With the increasing pace of science and technology advances, there were 19 drugs with new approvals for cancer treatment in 2018 according to “CenterWatch” (n.d.). Despite the excitement of tapping into the …
Proton Therapy Coming to Kansas City with Opening of Provision CARES Proton Therapy Center
Source: Provision Solutions From: PR Newswire Provision Healthcare announces the expansion of the Provision CARES Cancer Network with plans to develop the Provision CARES Cancer Center and Proton Therapy Center in Kansas City, KS. The center will be the first to open in Kansas, located in the Lenexa community of Kansas City to serve patients in the area and surrounding region …
Many Older Hospitalized Patients with Cancer Experience Malnutrition
Source: Wiley Research News From: PR Newswire Results from a new study indicate that older hospitalized patients with cancer may have a high risk of being malnourished and experiencing symptoms such as no appetite and nausea, according to findings published early online in CANCER, a peer-reviewed journal of the American Cancer Society. Many individuals with cancer experience malnutrition, which can …
Cancer accounts for more than one-quarter of new drug approvals, analysis finds
By: Alaric DeArment From: medcitynews.com Overall, the report, from the Tufts Center for the Study of Drug Development, found that new cancer drug approvals since 2010 have increased by 4 percent since the 1980s. More than one-quarter of the drugs that have received Food and Drug Administration approval have been for cancers, according to a new analysis. The analysis, by …